Recently, CircuTech Bio (Shanghai) Co., Ltd. (hereinafter referred to as “CircuTech Bio”) and Wecomput (Shanghai) Technology Co., Ltd. (hereinafter referred to as “Wecomput”) signed an agreement to deeply collaborate in the field of macromolecular innovative drug research and development, jointly working on the development of antibody drugs.
CircuTech Bio boasts extensive experience and a comprehensive biological experimental platform in the field of antibody drug research and development. Wecomput offers a protein design platform based on cutting-edge AI and biophysical computing technologies. By complementing each other’s strengths and integrating wet and dry lab approaches, the two companies aim to co-develop next-generation antibody drugs and related technology platforms, promoting the transformation of innovative achievements to benefit more patients.
Professor Junling Liu, Chairman of CircuTech Bio, stated:
“CircuTech is dedicated to exploring novel pathogenic mechanisms and developing innovative drugs across multiple fields. As an innovative drug development enterprise integrating production, academia, research, and investment, we actively develop and apply various highly promising innovative technology platforms to drive drug research and development. We recognize the immense potential of AI technology in the field of drug development and hope to leverage this technology to accelerate our innovative drug development process, creating a highly competitive international drug pipeline to address unmet clinical needs.”
Dr. Hu Ge, CEO of Wecomput, commented:
“CircuTech Bio is an emerging biotechnology company committed to original innovation, with original research achievements and relevant transformation experience in multiple disease fields. They possess a forward-looking vision and relentless pursuit of technological innovation. Wecomput has extensive experience in computation-driven antibody design. We are delighted to achieve deep collaboration with CircuTech Bio. This marks a solid step in applying our AI technology to the field of macromolecular biopharmaceuticals. We look forward to working closely together, complementing each other’s strengths, to enable patients to access more effective drugs as soon as possible.”
About XunYao Biopharma
XunYao Biopharma was founded by Professor Junling Liu from the Shanghai Jiao Tong University School of Medicine and his research team. The registered shareholders include Professor Junling Liu, Shanghai Pharmaceutics’ subsidiary Shanghai JiaoLian Drug Research and Development Co., Ltd., Shanghai Second Medical Investment Management Co., Ltd., and Shanghai Biomedical Industry Equity Investment Fund. The company focuses on antibody drugs, nucleic acid drugs, and cell therapy, dedicated to exploring new pathogenic mechanisms and developing innovative drugs in multiple fields. XunYao Biopharma is the first achievement of the “Shanghai Pharmaceutics-Jiao Tong University Medical School Innovation Results” incubation platform, which is a collaboration of industry, academia, research, and capital.
Professor Junling Liu is a recipient of the National Science Fund for Distinguished Young Scholars, a Distinguished Professor at Shanghai Jiao Tong University, and a Shanghai Distinguished Professor. He has been engaged in basic and translational research on bleeding and coagulation for over 20 years, leading several major national projects. His research has been published in leading international journals such as Blood, Circulation, Cell Metabolism, Hepatology, and JCI. His achievements have been recognized with the First Prize of the Ministry of Education’s Science and Technology Progress Award and the Second Prize of the National Science and Technology Progress Award.
About Wecomput
Wecomput is dedicated to driving innovative drug development through computational technology, benefiting human health. Wecomput integrates biophysics, AI, HPC, and generative biology to create a unique platform for drug molecule generation, simulation, and design, potentially revolutionizing traditional drug discovery methods and accelerating the development of innovative drugs such as proteins, antibodies, and mRNA.
The core team members of Wecomput come from internationally renowned AI pharmaceutical companies, leading pharmaceutical companies, well-known internet companies, and top universities (985 universities in China). They have rich experience, deep understanding, and great enthusiasm in the intersecting fields of biopharmaceuticals, artificial intelligence, and software development. The company has research centers in Beijing, Shanghai, and Guangzhou, and has been recognized as a Zhongguancun High-Tech Enterprise and a member of the NVIDIA Inception Program, with investment from Sequoia Capital. Since its founding in 2015, Wecomput has served hundreds of clients worldwide, including numerous biopharmaceutical companies, universities, hospitals, and research institutions, and has conducted multiple collaborative drug development pipelines.
Wecomput has developed the WeMol platform, a proprietary molecular digital intelligent computing platform that supports the digital computation and AI modeling of proteins, antibodies, nucleic acids, chemical drugs, biomaterials, and natural products. WeMol features a streaming architecture, supports low-code custom development and flexible expansion, and its core algorithm modules surpass or rival international mainstream commercial software in terms of speed, accuracy, and storage efficiency.